Series A · Biotech · Gothenburg, Sweden · Founded 2014 · 11–50 employees
VERIGRAFT develops personalized tissue-engineered transplants using a breakthrough technology platform that transforms donated tissue into patient-specific grafts without requiring immunosuppression. Their lead product P-TEV addresses chronic venous insufficiency, completing Phase I/II trials with positive safety data. The company has raised approximately €18 million in equity and grant funding, including a recent €1.2 million Eurostars grant. Founded in 2014 and based at Gothenburg University, they are advancing toward pivotal Phase II trials for market approval by 2027.
No open roles listed right now.